Daniel Markett

Daniel Markett

Auto-generated profile, based on publicly available information

Daniel Markett

Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2023 in Nature Cell Biology
Verified
Journal Article
Open access
PDF file
ANAlbertas Navickas
Albertas Navickas
HAHosseinali Asgharian
Hosseinali Asgharian
JWJuliane Winkler
Juliane Winkler
LFLisa Fish
Lisa Fish
KGKristle Garcia
Kristle Garcia
HGHani Goodarzi
Hani Goodarzi
Cancer cells often co-opt post-transcriptional regulatory mechanisms to achieve pathologic expression of gene networks that drive metastasis. Translational control is a major regulatory hub in oncogenesis; however, its effects on cancer progression remain poorly understood. Here, to address this, we used ribosome profiling to compare genome-wide translation efficiencies of poorly and highly metastatic breast cancer cells and patient-derived xenografts. We developed dedicated regression-based methods to analyse ribosome profiling and alternative polyadenylation data, and identified heterogeneous nuclear ribonucleoprotein C (HNRNPC) as a translational controller of a specific mRNA regulon. We found that HNRNPC is downregulated in highly metastatic cells, which causes HNRNPC-bound mRNAs to undergo 3′ untranslated region lengthening and, subsequently, translational repression. We showed that modulating HNRNPC expression impacts the metastatic capacity of breast cancer cells in xenograft mouse models. In addition, the reduced expression of HNRNPC and its regulon is associated with the worse prognosis in breast cancer patient cohorts.

11 May 2023 in Nature Cancer
Verified
Journal Article
Open access
PDF file
BCBruce Culbertson
Bruce Culbertson
KGKristle Garcia
Kristle Garcia
DMDaniel Markett
Daniel Markett
HAHosseinali Asgharian
Hosseinali Asgharian
LCLi Chen
Li Chen
HGHani Goodarzi
Hani Goodarzi
Antisense RNAs are ubiquitous in human cells, yet their role is largely unexplored. Here we profiled antisense RNAs in the MDA-MB-231 breast cancer cell line and its highly lung metastatic derivative. We identified one antisense RNA that drives cancer progression by upregulating the redox enzyme NADPH quinone dehydrogenase 1 (NQO1), and named it NQO1-AS. Knockdown of either NQO1 or NQO1-AS reduced lung colonization in a mouse model, and investigation into the role of NQO1 indicated that it is broadly protective against oxidative damage and ferroptosis. Breast cancer cells in the lung are dependent on this pathway, and this dependence can be exploited therapeutically by inducing ferroptosis while inhibiting NQO1. Together, our findings establish a role for NQO1-AS in the progression of breast cancer by regulating its sense mRNA post-transcriptionally. Because breast cancer predominantly affects females, the disease models used in this study are of female origin and the results are primarily applicable to females.